La insuficiencia cardiaca por disfunción sistólica hace referencia a un síndrome clínico caracterizado por signos y/o síntomas de insuficiencia cardiaca en el contexto de una enfermedad estructural cardiaca que provoca una disminución de la función contráctil del ventrículo izquierdo. En las guías de tratamiento actuales se insiste en la importancia del diagnóstico y el tratamiento de la disfunción ventricular izquierda sin síntomas de insuficiencia cardiaca. Se hace necesaria la implementación de la evidencia científica disponible en el tratamiento de todos los pacientes atendidos por esta enfermedad, des de el consejo dietético hasta los dispositivos más complejos. Desconocemos con exactitud la respuesta al tratamiento en subgrupos de pacientes infrarrepresentados en los grandes ensayos clínicos. Tras la reciente publicación de las guías europeas y americanas, en el presente capítulo se hace una revisión del tratamiento médico indicado en los pacientes con insuficiencia cardiaca por disfunción sistólica.
Palabras clave
Insuficiencia cardiaca
Disfunción sistólica
Tratamiento
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
M.M. Redfield.
Heart failure: an epidemic of uncertain proportions.
N Engl J Med, (2002), 347 pp. 1442-1444
[2.]
D. Levy, S. Kenchaiah, M.G. Larson, E.J. Benjamin, M.J. Kupka, K.K. Ho, et al.
Long-term trends in the incidence of and survival with heart failure.
N Engl J Med, (2002), 347 pp. 1397-1402
[3.]
F. Rodríguez-Artalejo, B. Banegas Jr.
Insuficiencia cardiaca: de los ensayos clínicos a la práctica clínica habitual.
Rev Esp Cardiol, (2002), 55 pp. 563-564
[4.]
A.J. Muñoz García, G.C. Sánchez, M.F. Jiménez Navarro, G.E. De Teresa.
Aplicabilidad de los resultados de los ensayos clínicos de insuficiencia cardiaca a los pacientes mayores.
Med Clin (Barc), (2005), 124 pp. 558
[5.]
F. Rodríguez-Artalejo, B. Banegas Jr, P. Guallar-Castillon.
Epidemiología de la insuficiencia cardiaca.
Rev Esp Cardiol, (2004), 57 pp. 163-170
[6.]
C. Berry, D.R. Murdoch, J.J. McMurray.
Economics of chronic heart failure.
Eur J Heart Fail, (2001), 3 pp. 283-291
[7.]
M. Giverts, W. Colucci, E. Braunwald.
Clinical aspects of heart failure; pulmonary edema, high-output failure.
7th ed., Elsevier Saunders, pp. 539-568
[8.]
J.G. Cleland, K. Swedberg, F. Follath, M. Komajda, A. Cohen-Solal, J.C. Aguilar, et al.
The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.
Eur Heart J, (2003), 24 pp. 442-463
[9.]
K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, et al.
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.
Eur Heart J, (2005), 26 pp. 1115-1140
[10.]
S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, et al.
ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society.
Circulation, (2005), 112 pp. 1825-1852
[11.]
J. Gonseth, P. Guallar-Castillon, J.R. Banegas, F. Rodríguez-Artalejo.
The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports.
Eur Heart J, (2004), 25 pp. 1570-1595
[12.]
S. Ojeda, M. Anguita, M. Delgado, F. Atienza, C. Rus, A.L. Granados, et al.
Short – and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme?.
Eur J Heart Fail, (2005), 7 pp. 921-926
[13.]
P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, et al.
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial.
Lancet, (2003), 362 pp. 7-13
[14.]
M.C. Shibata, M.D. Flather, D. Wang.
Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure.
Eur J Heart Fail, (2001), 3 pp. 351-357
[15.]
M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krum, P. Mohacsi, et al.
Effect of carvedilol on survival in severe chronic heart failure.
N Engl J Med, (2001), 344 pp. 1651-1658
[16.]
R. Willenheimer, D.J. Van Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum, et al.
Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.
Circulation, (2005), 112 pp. 2426-2435
[17.]
W.A. Gattis, C.M. O’Connor, D.S. Gallup, V. Hasselblad, M. Gheorghiade.
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
J Am Coll Cardiol, (2004), 43 pp. 1534-1541
[18.]
M.D. Flather, S. Yusuf, L. Kober, M. Pfeffer, A. Hall, G. Murray, et al.
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.
Lancet, (2000), 355 pp. 1575-1581
[19.]
K.K. Teo, S. Yusuf, M. Pfeffer, C. Torp-Pedersen, L. Kober, A. Hall, et al.
Effects of long-term treatment with angiotensin-convertingenzyme inhibitors in the presence or absence of aspirin: a systematic review.
Lancet, (2002), 360 pp. 1037-1043
[20.]
K.J. Harjai, S. Solis, A. Prasad, J. Loupe.
Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure.
Int J Cardiol, (2003), 88 pp. 207-214
[21.]
M. Cicardi, L.C. Zingale, L. Bergamaschini, A. Agostoni.
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment.
Arch Intern Med, (2004), 164 pp. 910-913
[22.]
E. Roig, F. Pérez-Villa, M. Morales, W. Jimenez, J. Orus, M. Heras, et al.
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Eur Heart J, (2000), 21 pp. 53-57
[23.]
R.M. Van de Wal, D.J. Van Veldhuisen, W.H. Van Gilst, A.A. Voors.
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?.
Eur Heart J, (2005), 26 pp. 2361-2367
[24.]
J.N. Cohn, G. Tognoni.
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
N Engl J Med, (2001), 345 pp. 1667-1675
[25.]
C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial.
Lancet, (2003), 362 pp. 772-776
[26.]
J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson, et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet, (2003), 362 pp. 767-771
[27.]
B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Pérez, et al.
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
N Engl J Med, (1999), 341 pp. 709-717
[28.]
B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, et al.
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med, (2003), 348 pp. 1309-1321
[29.]
B. López, R. Querejeta, A. González, E. Sánchez, M. Larman, J. Díez.
Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.
J Am Coll Cardiol, (2004), 43 pp. 2028-2035
[30.]
N.R. Loon, C.S. Wilcox, R.J. Unwin.
Mechanism of impaired natriuretic response to furosemide during prolonged therapy.
Kidney Int, (1989), 36 pp. 682-689
[31.]
M. Gheorghiade, W.A. Gattis, C.M. O’Connor, K.F. Adams Jr., U. Elkayam, A. Barbagelata, et al.
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
JAMA, (2004), 291 pp. 1963-1971
[32.]
S.S. Rathore, Y. Wang, H.M. Krumholz.
Sex-based differences in the effect of digoxin for the treatment of heart failure.
N Engl J Med, (2002), 347 pp. 1403-1411
[33.]
B.M. Massie, S.G. Fisher, M. Radford, P.C. Deedwania, B.N. Singh, R.D. Fletcher, et al.
Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators.
Circulation, (1996), 93 pp. 2128-2134
[34.]
C. Torp-Pedersen, M. Moller, P.E. Bloch-Thomsen, L. Kober, E. Sandoe, K. Egstrup, et al.
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
N Engl J Med, (1999), 341 pp. 857-865
[35.]
A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D’Agostino Jr, K. Ferdinand, et al.
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
N Engl J Med, (2004), 351 pp. 2049-2057
Copyright ©
2006. Sociedad Española de Cardiología